

3.1.3 (QnM) Number of research projects/clinical trials funded by government, industries and non-governmental agencies during the last five years.

Year	Name of the Principal Investigator	Title of the project	Name of the Funding agency
2017-2018	Miss.Supriya	Neutropic Leukocytosis as a marker of Myocardial Ischemia	ICMR
2018-2019	Dr Suguna Dumpala	Evaluation of <6yrs for active TB by CBNAT of adult tuberculosis and treat them accordingly in Rangareddy District ,Telangana state India.	State TB cell
2018-2019	Dr Suguna Dumpala	Active case finding at Bowrampet Grampanchayat	State TB cell
2019-2020	Miss.Hanusree Ganta	Utilization of anti natal care services in RHTC practice area of tertiary care hospital ,Hyderabad .Telangana.	ICMCR
2019-2020	Bhavana k	A study of Menstruation related sociocultural challenges and awareness in girl school children in hyderabad.	ICMCR
2019-2020	Sobhia Zubair	Breaking bad news- a qualitative study understating the art of breaking bad news	ICMCR
2020-2021	Dr. N Srinivas Rao	A phase III, randomised, multi-centre, double blind, placebo controlled, study, to evaluate efficacy, safety & immunogenicity of Novel Corona Virus - 2019-Ncov vaccine candidate of M's Cadila Healthcare Limited	ZYDUS LIFESCIENCES LIMITED
2020-2021	Dr.Ajmera Prakash	A Prospective, Multicenter, Randomized, Comparative, Parallel Group Clinical Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Intravenous Injection of Tenecteplase(Hetero Biopharma Limited) and Reference Medicinal Product (RMP Tenecteplase, BoehringerIngelheim) in Adults for the Thrombolytic Treatment of Suspected Myocardial Infarction with Persistent ST Elevation.Protocol ID: HCR/III/TENESTEMI/08/2020	Hetero
2020-2021	Dr.Ajmera Prakash	Ultra ThinstrUt versus XiencE in a diabetic population with multi-Vessel Diseases -2- India study (TUXEDO - 2 INDIA)	Batra Hospital and medical research centre
2020-2021	Dr.Archana Andhavarapu	A Phase 2,Randomized,Double blind,Placebo-controlled study on the safety and efficacy of Niclosamide in patients with COVID-19 with Gastrointestinal infection Protocol Number:AZ-NICL-COV-1	CBCC Global research
2020-2021	Dr.Archana Andhavarapu	A Phase III, Randomized,Controlled,Open-Label study to evaluate the efficacy and safety of Pegylated Interferon Alfa-2b in the treatment of adult patients diagnosed with SARS-Cov-2 (COVID-19)Protocol Number:PEGI.20.005	Cadila Healthcare Limited

2021-2022	Dr.K.Praveen	A Phase 2,Randomized,Double blind,Placebo-controlled,Two-arm study to evaluate the efficacy and safety of HydroxyprogesteroneCaproate Intramuscular Injection Plus Dexamethasone compared to Dexamethasone alone in patients with moderate COVID-19 disease(Non-intubated,Nonmechanical ventilation)Protocol Number:HPC-EG-009A-2.2	CBCC Global research
2021-2022	Dr.Leelabati Toppo	'A Phase 2, Dose-Ranging, Multicenter, Randomized,Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of AQCH Tablets in Adult Patients with Dengue Fever'Protocol No.: ICR/20/002;	Sun pharma laboratories Ltd
2021-2022	Dr.Ram Prahlad	A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence,Crossover, Multiple Dose, Steady state Bioequivalence Study of Sunitinib Malate Capsules 50mg of EugiaPharma Specialities Limited (A Joint venture of AurobindoPharma Limited & Celon Laboratories Limited), India (Test) with Sutent® (Sunitinib Malate) capsules 50 mg ofPfizer Labs, USA (Reference) in adult patients with advanced renal cell carcinoma alreadyreceiving stable dose of Sunitinib Malate Capsules 50 mg under fasting conditions.	Clinsync Clinical Research Pvt. Ltd
2021-2022	Dr.Leelabati Toppo	A Phase III randomized open label multi-center study to compare immunogenicity and safety of BBV154 with COVAXIN®, and to assess Lot to Lot Consistency of BBV154 in Healthy Volunteers.Protocol No: BBIL/BBV154-III/2022	Bharat Biotech International Limited
2021-2022	Dr.Leelabati Toppo	A phase 2 randomised, multicentric, clinical trial of heterologus Prime-Boost Combination of SARS CoV-2 Vaccines to evaluate the immunogenicity & safety of BBV152(COVAXIN) with BBV154 (Adeno Intranasal COVID 19 VACCINE) in healthy volunteers Protocol Number:BBIL-BBV152/154-2021	Bharat Biotech International Limited
2022-2023	Dr.Pradeep Reddy	A phase III randomised, modified double blinded, multi centric comparative study to evaluate the non-inferiority of immunogenicity & safety of single strain oral cholera vaccine Hillchol (BBV131) to the comparator vaccine Shanchol along with lot to lot consistency of Hillchol (Safety study)	Bharat Biotech International Limited
2022-2023	Dr.Subhash Reddy	A multicentric, randomised, double blind, placebo controlled study to evaluate the safety & efficacy of Apremilast topical gel, 2%w/w in adult patients with mild to moderate plaque psoriasis : Phase III clinical trial	Aizant drug research solutions private limited

2022-2023	Dr.Suma Priya	A Prospective, Multi-center, Single-arm, Phase IV Study to Assess the Safety and Efficacy of Amoxicillin and Potassium Clavulanate Oral Suspension in Children With Upper Respiratory Tract Infection (URTI) or Lower Respiratory Tract Infection (LRTI). (ICR/22/010)"	Sun pharma laboratories Ltd
2022-2023	Dr.Suma Priya	A phase III randomised, modified double blinded, multi centric comparartive study to evaluate the non-interiority of immunogenicity & safety of single strain oral	Bharat Biotech International Limited

Suma Priya

DEAN

Malla Reddy Medical College for Women